Cargando…
Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
Patients with early-stage non-small-cell lung cancer (NSCLC) are candidates for curative surgery; however, despite multiple advances in lung cancer management, recurrence rates remain high. Adjuvant chemotherapy has been demonstrated to significantly prolong overall survival (OS), but this benefit i...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546659/ https://www.ncbi.nlm.nih.gov/pubmed/34733613 http://dx.doi.org/10.5306/wjco.v12.i10.912 |
_version_ | 1784590230877110272 |
---|---|
author | Sotelo, Miguel J Luis García, José Torres-Mattos, Cesar Milián, Héctor Carracedo, Carlos González-Ruiz, María Ángeles Mielgo-Rubio, Xabier Trujillo-Reyes, Juan Carlos Couñago, Felipe |
author_facet | Sotelo, Miguel J Luis García, José Torres-Mattos, Cesar Milián, Héctor Carracedo, Carlos González-Ruiz, María Ángeles Mielgo-Rubio, Xabier Trujillo-Reyes, Juan Carlos Couñago, Felipe |
author_sort | Sotelo, Miguel J |
collection | PubMed |
description | Patients with early-stage non-small-cell lung cancer (NSCLC) are candidates for curative surgery; however, despite multiple advances in lung cancer management, recurrence rates remain high. Adjuvant chemotherapy has been demonstrated to significantly prolong overall survival (OS), but this benefit is modest and there is an urgent need for effective new therapies to provide a cure for more patients. The high efficacy of tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor-mutated (EGFR) in patients with advanced EGFR-mutated NSCLC has led to the evaluation of these agents in early stages of the disease. Multiple clinical trials have evaluated the safety and efficacy of EGFR TKIs as an adjuvant treatment, in patients with resected EGFR-mutated NSCLC, and shown that they significantly prolong disease-free survival (DFS), but this benefit does not translate to OS. Recently, an interim analysis of the ADAURA trial demonstrated that, surprisingly, osimertinib improved DFS. This led to the study being stopped early, leaving many unanswered questions about its potential effect on OS and its incorporation as a standard adjuvant treatment in this patient subgroup. These targeted agents are also being evaluated in locally-advanced disease, with promising results, although prospective studies with larger sample sizes are needed to confirm these results. In this article, we review the most relevant studies on the role of EGFR TKIs in the management of early-stage EGFR-mutated NSCLC. |
format | Online Article Text |
id | pubmed-8546659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-85466592021-11-02 Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer Sotelo, Miguel J Luis García, José Torres-Mattos, Cesar Milián, Héctor Carracedo, Carlos González-Ruiz, María Ángeles Mielgo-Rubio, Xabier Trujillo-Reyes, Juan Carlos Couñago, Felipe World J Clin Oncol Minireviews Patients with early-stage non-small-cell lung cancer (NSCLC) are candidates for curative surgery; however, despite multiple advances in lung cancer management, recurrence rates remain high. Adjuvant chemotherapy has been demonstrated to significantly prolong overall survival (OS), but this benefit is modest and there is an urgent need for effective new therapies to provide a cure for more patients. The high efficacy of tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor-mutated (EGFR) in patients with advanced EGFR-mutated NSCLC has led to the evaluation of these agents in early stages of the disease. Multiple clinical trials have evaluated the safety and efficacy of EGFR TKIs as an adjuvant treatment, in patients with resected EGFR-mutated NSCLC, and shown that they significantly prolong disease-free survival (DFS), but this benefit does not translate to OS. Recently, an interim analysis of the ADAURA trial demonstrated that, surprisingly, osimertinib improved DFS. This led to the study being stopped early, leaving many unanswered questions about its potential effect on OS and its incorporation as a standard adjuvant treatment in this patient subgroup. These targeted agents are also being evaluated in locally-advanced disease, with promising results, although prospective studies with larger sample sizes are needed to confirm these results. In this article, we review the most relevant studies on the role of EGFR TKIs in the management of early-stage EGFR-mutated NSCLC. Baishideng Publishing Group Inc 2021-10-24 2021-10-24 /pmc/articles/PMC8546659/ /pubmed/34733613 http://dx.doi.org/10.5306/wjco.v12.i10.912 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Sotelo, Miguel J Luis García, José Torres-Mattos, Cesar Milián, Héctor Carracedo, Carlos González-Ruiz, María Ángeles Mielgo-Rubio, Xabier Trujillo-Reyes, Juan Carlos Couñago, Felipe Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer |
title | Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer |
title_full | Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer |
title_fullStr | Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer |
title_full_unstemmed | Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer |
title_short | Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer |
title_sort | recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546659/ https://www.ncbi.nlm.nih.gov/pubmed/34733613 http://dx.doi.org/10.5306/wjco.v12.i10.912 |
work_keys_str_mv | AT sotelomiguelj recentadvancesandnewinsightsinthemanagementofearlystageepidermalgrowthfactorreceptormutatednonsmallcelllungcancer AT luisgarciajose recentadvancesandnewinsightsinthemanagementofearlystageepidermalgrowthfactorreceptormutatednonsmallcelllungcancer AT torresmattoscesar recentadvancesandnewinsightsinthemanagementofearlystageepidermalgrowthfactorreceptormutatednonsmallcelllungcancer AT milianhector recentadvancesandnewinsightsinthemanagementofearlystageepidermalgrowthfactorreceptormutatednonsmallcelllungcancer AT carracedocarlos recentadvancesandnewinsightsinthemanagementofearlystageepidermalgrowthfactorreceptormutatednonsmallcelllungcancer AT gonzalezruizmariaangeles recentadvancesandnewinsightsinthemanagementofearlystageepidermalgrowthfactorreceptormutatednonsmallcelllungcancer AT mielgorubioxabier recentadvancesandnewinsightsinthemanagementofearlystageepidermalgrowthfactorreceptormutatednonsmallcelllungcancer AT trujilloreyesjuancarlos recentadvancesandnewinsightsinthemanagementofearlystageepidermalgrowthfactorreceptormutatednonsmallcelllungcancer AT counagofelipe recentadvancesandnewinsightsinthemanagementofearlystageepidermalgrowthfactorreceptormutatednonsmallcelllungcancer |